With the introduction of every new technology, tactic, or gimmick comes what I call a tactical scrum. It’s like watching young kids play their first game of T-ball or soccer.
With the introduction of every new technology, tactic, or gimmick comes what I call a tactical scrum. It’s like watching young kids play their first game of T-ball or soccer. No matter how much instruction the coach gives on field position or game play, the second that ball is hit or kicked, the entire team runs toward it. The result is a scrum of little people all chasing the ball.
Which bring us to today’s pharma marketers.
Admittedly they’re a bit taller, but they do tend to form a tactical scrum around new technology, or as we often call it, the new shiny object. Years ago it was pop-up mailers, then e-mail programs, now almost anything digital, social, or content driven. Product managers often seem wired or instinctively driven to chase the new and different whether it aligns with their brand strategy or not. In spite of their marketing training and rational thinking, they are lured by the new and different to break ranks, leave their position, and run headlong toward the ball.
Now there’s nothing wrong with a shiny object-iPads were breakthrough and have shown to be terrifically effective-as long as it supports a brand strategy, focuses on the target audience, and delivers the right message. Agencies, you need to make sure the shiny object you’re about to propose supports brand objectives. Clients, be careful you’re not craving that object just because it’s shiny or because the brand manager in the next office has one.
As the T-ball coach would say: cover your bases. Make sure you know the game and have a plan for when that ball comes to you. Only then should you be trying out a new trick play.
Al Topin is president at Topin & Associates. He can be reached at atopin@topin.com.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.